8-K: CorMedix Announces Strong Preliminary Q4 Results and Business Expansion

CorMedix reports preliminary Q4 2024 revenue of approximately $31 million and expects adjusted EBITDA to exceed $12 million, alongside an expansion into the inpatient hospital segment.

Summary

• CorMedix announced preliminary unaudited net revenue of approximately $31 million for the fourth quarter of 2024 and approximately $43 million for the full year 2024.
• The company expects its Q4 2024 adjusted EBITDA to exceed $12 million.
• CorMedix is currently shipping DefenCath to all three of its midsized dialysis operator customers, with continuous ordering throughout the quarter.
• The company has over $25 million in open purchase orders scheduled for delivery in the first quarter of 2025.
• CorMedix is working with a large dialysis operator to begin DefenCath implementation in the first half of 2025, targeting 4,000 patients in the second half of 2025.
• An expanded deployment effort in the inpatient hospital segment will begin in Q1 2025, with Syneos Health engaged to build a dedicated sales team.
• The company submitted a final clinical study protocol for DefenCath in Total Parenteral Nutrition (TPN) to the FDA in Q4, with study enrollment expected to begin in H1 2025.
• Patient enrollment in the pediatric study for DefenCath in pediatric hemodialysis is expected to begin in H2 2025.
• CorMedix estimates the expanded inpatient deployment and internal commercial realignment to be cost neutral on overall sales and marketing expense in 2025.
• Preliminary operating expense guidance for FY 2025 is $72-$78 million, excluding non-cash and one-time items, with the increase largely driven by R&D spending.
• The company reports preliminary unaudited cash and short-term investments of approximately $52 million as of December 31, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong preliminary financial results, exceeding breakeven guidance, and strategic expansion plans. The company's progress in clinical trials and sales growth contributes to the positive outlook.

Positives

• The company exceeded its breakeven guidance for year-end 2024.
• CorMedix is experiencing continuous ordering of DefenCath from its midsized dialysis operator customers.
• The company has a strong backlog of over $25 million in open purchase orders.
• CorMedix is expanding its market reach into the inpatient hospital segment.
• The company is progressing with clinical studies for DefenCath in TPN and pediatric hemodialysis.
• The expanded inpatient deployment is expected to be cost neutral on overall sales and marketing expense in 2025.

Negatives

• The reorganization of the field team will result in some existing roles being transitioned or eliminated.
• The increase in operating expenses for 2025 is largely driven by R&D spending on previously announced clinical initiatives.

Risks

• The preliminary financial results are subject to change upon completion of the internal review process and annual audit procedures.
• The company's ability to achieve the large dialysis operator's targeted patient utilization of 4,000 patients in H2 2025 is not guaranteed.
• The success of the expanded inpatient deployment and the new sales team is subject to execution risks.
• The timing of study enrollment for the TPN and pediatric hemodialysis studies may be subject to delays.

Future Outlook

CorMedix expects to continue executing on its key objectives, particularly around the outpatient launch, and is committed to growing DefenCath across different settings of care. The company anticipates updating investors as it continues to execute over the coming months.

Management Comments

• Joe Todisco, CorMedix CEO, stated he is proud to announce the preliminary Q4 results, including surpassing the guidance of becoming breakeven by year-end 2024.
• The CEO is pleased with the implementation efforts seen thus far from key customers in the outpatient segment.
• The agreement for inpatient expansion with Syneos Health reinforces the company's commitment to grow DefenCath across settings of care.
• The CEO believes the company begins 2025 in a strong position.

Industry Context

This announcement reflects a positive trend in the biopharmaceutical industry, where companies are focusing on expanding the market reach of their approved products. The move into the inpatient hospital segment is a strategic step to increase DefenCath's adoption and market penetration. The engagement of Syneos Health is a common practice for companies looking to accelerate their sales efforts.

Comparison to Industry Standards

• CorMedix's revenue growth and EBITDA performance are positive indicators compared to other small-cap biopharmaceutical companies in the commercialization phase.
• The company's focus on expanding into the inpatient market is similar to strategies employed by other companies launching new medical products.
• The engagement of Syneos Health for sales expansion is a common practice in the industry, similar to companies like Amarin and Alkermes who have used contract sales organizations to expand their reach.
• The reported cash position of $52 million is a reasonable amount for a company of this size, but will need to be monitored against the planned R&D and sales expansion costs.
• The company's progress in clinical trials for TPN and pediatric hemodialysis is in line with industry standards for expanding the indications of approved drugs.

Stakeholder Impact

• Shareholders will likely react positively to the strong preliminary financial results and expansion plans.
• Employees may experience changes due to the reorganization of the field team.
• Customers, particularly dialysis operators and hospitals, will benefit from the increased availability of DefenCath.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company's financial performance favorably.

Next Steps

• CorMedix will continue to ship DefenCath to its midsized dialysis operator customers.
• The company will work with its large dialysis operator customer to begin DefenCath implementation in the first half of 2025.
• CorMedix will begin an expanded deployment effort in the inpatient hospital segment in Q1 2025.
• The company will begin study enrollment for DefenCath in TPN in H1 2025.
• Patient enrollment in the pediatric study for DefenCath in pediatric hemodialysis is expected to begin in H2 2025.
• CorMedix will provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release.

Key Dates

Keywords

DefenCath, dialysis, EBITDA, revenue, biopharmaceutical, clinical trials, inpatient, outpatient, hemodialysis, TPN, Syneos Health